COST NO FEE

BOSTON MEDICAL CENTER CORPORATION - NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE

PIID: 75N94025F00001
Signed Date: Jan 26, 2026Effective Date: Aug 1, 2025End Date: Closed on Apr 30, 2026
Award $
$100K
Vendor
BOSTON MEDICAL CENTER CORPORATION
NAICS
541714
Signed Date
Jan 26, 2026

Key Details

Dollars Obligated
$99,921.01
Base & All Options
Awarding Sub-Agency
National Institutes of Health
Product Service Code
AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Extent Competed
FULL AND OPEN COMPETITION
Number of Offers
6
Place of Performance
BOSTON, MA, 021182908, CD-MA-07

Description

NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE

Context & Analysis

On Jan 26, 2026, Department of Health and Human Services obligated $99,921.01 to BOSTON MEDICAL CENTER CORPORATION for nichd: r&d: a phase 2b study to evaluate the efficacy and safety of subcutaneous levonorgestrel butanoate for female contraception: non-severable. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: full and open competition with 6 offers received. Performance is located in BOSTON, MA. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.

Contractor Information

UEI: JZ8RQC4EMDZ5
CAGE Code: 09PZ2
Location: BOSTON, MA
View Full Record on USASpending.gov

Stay Updated

Get notified about new opportunities matching your interests.

Related